Investigating the Influence of Glycosylation on Protein Conformation and Dynamics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Investigating the Influence of Glycosylation on Protein Conformation and Dynamics
The authors review and discuss the influence of glycans on the conformation of a representative IgG1 biopharmceutical using H/DX-MS as an analytical tool.


Pharmaceutical Technology
Volume 34, pp. s12-s17

15. S.W. Englander and L. Mayne, Annu. Rev. Biophys. Biomol. Struct. 21, 243–265 (1992).

16. V. Katta and B.T. Chait, Rapid Comm. Mass Spec. 5 (4), 214–217 (1991).

17. Z. Zhang and D.L. Smith, Protein Sci. 2 (4), 522–531 (1993).

18. S.W. Englander and N.R. Kallenbach, Q. Rev. Biophys. 16 (4), 134 (1983).

19. T.E. Wales and J.R. Engen, Mass Spectrom. Rev. 25 (1), 158–170 (2006).

20. A.N. Hoofnagle, K.A. Resing, and N.G. Ahn, Annu. Rev. Biophys. Biomol. Struct. 32, 1–25 (2003).

21. J.G. Mandell, A.M. Falick, and E.A. Komives EA, Anal. Chem. 70 (19), 3987–3995 (1998).

22. O.H. Brekke and I. Sandlie, Nat. Rev. Drug Discov. 2 (1), 52–62 (2003).

23. O. Leav, Nat. Rev. Immunol. 10 (5), 297–297 (2010).

24. D. Houde et al., Anal. Chem. 81 (7), 2644–2651 (2009).

25. H.E. Chadd and S.M. Chamow, Curr. Opin. Biotechnol. 12 (2), 188–194 (2001).

26. Y. Mimura et al., Mol. Immunol. 37 (12–13), 697–706 (2000).

27. D. Houde , Mol. Cell. Proteomics 9 (8), 1716–1728 (2010).

28. Y. Yamaguchi et al., Biochem. Biophys. Acta 1760 (4), 693–700 (2006).

29. P. Sondermann et al., Nature 406 (6793), 267–273 (2000).

30. H. Liu and C.G. Bulseco, Immunol. Lett. 106 (2), 144–153 (2006).

31. S. Krapp et al., .J Mol. Biol. 325 (5), 979–989 (2003).

32. A. Okazaki et al., J. Mol. Biol. 336 (5), 1239–1249 (2004).

33. S. Radaev et al., J. Biol. Chem. 276 (19), 16469–16477 (2001).

34. D. Shental–Bechor and Y. Levy, Curr. Opin. Struct. Biol. 19 (5), 524–533 (2009).

35. K.D. Rand et al., Anal. Chem. 81 (14), 5577–5584 (2009).

36. E.O. Saphire et al., Science 293 (5532), 1155–1159 (2001).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here